Study in Subjects With Small Primary Choroidal Melanoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Official Title

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of choroidal melanoma
Exclusion Criteria:
  1. - Have known contraindications or sensitivities to the study drug


Prithvi Mruthyunjaya, MD, MHS
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologic oncologist, Retina specialist, Ophthalmologist
Professor of Ophthalmology and, by courtesy, of Radiation Oncology

Contact us to find out if this trial is right for you.


Mariana Nunez